Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Immunol. 2009 Jul;132(1):1-9. doi: 10.1016/j.clim.2009.02.006. Epub 2009 Mar 24.

Advances in the pathogenesis and treatment of IBD.

Author information

1
Doris Duke Clinical Research Fellowship Program Carver College of Medicine, University of Iowa, Iowa City, IA 52242-1009, USA.

Abstract

Crohn's disease and ulcerative colitis are chronic remitting and relapsing inflammatory bowel diseases. We present a typical case of Crohn's disease in a young woman and discuss potential treatment options. Crohn's disease and ulcerative colitis likely result from interaction of multiple genetic and environmental risk and protective factors. Both are diseases ultimately caused by immune dysregulation. Medical therapy is with mesalamine compounds, corticosteroids, immunomodulators and/or biologics that target TNFalpha signaling or alpha4-integrin-mediated trafficking. Investigational agents include those targeted against other cytokines and costimulatory molecules or designed to promote immune regulation such as exposure to helminths which is a focus of this review.

PMID:
19321388
PMCID:
PMC2693446
DOI:
10.1016/j.clim.2009.02.006
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center